Amgen Inc. (AMGN)

188.29
1.70 0.91
NASDAQ : Health Technology
Prev Close 186.59
Open 187.55
Day Low/High 187.03 / 189.59
52 Wk Low/High 163.31 / 210.19
Volume 2.34M
Avg Volume 3.16M
Exchange NASDAQ
Shares Outstanding 622.28M
Market Cap 116.18B
EPS 12.70
P/E Ratio 15.21
Div & Yield 5.80 (2.82%)

Latest News

Markets Open Lower Friday, a Check on CVS Health After Last Night's Interview

We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes

Video: AAP Daily Rundown for Monday

Jeff and Zev discuss today's activity in the portfolio (the Amgen trim and the Nvidia initiation) and also answer a few member questions!

Trimming Amgen This Morning

This sale is about risk management and decreasing our downside exposure to a decision that is left to the courts.

Last Week's Portfolio Changes

We downgraded our ratings on two positions last week.

Weekly Roundup

Strong earnings boost shares in a rebound week for stocks.

Stocks Close Up on Signs of Progress in U.S.-China Trade Talks, Boeing Higher

Stocks Close Up on Signs of Progress in U.S.-China Trade Talks, Boeing Higher

Stocks close up on Friday amid hopes the U.S. and China are making progress on a trade pact and word that Boeing is speeding up its 737 MAX fixes.

Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations

Updates on 4 Portfolio Names

These stocks are moving on recent headlines.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Amgen And Jay Leno Partner To Sound The Alarm On High Cholesterol And Its Link To Heart Attack And Stroke In Patients Most At Risk

Amgen And Jay Leno Partner To Sound The Alarm On High Cholesterol And Its Link To Heart Attack And Stroke In Patients Most At Risk

If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1)

Weekly Roundup

With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.

Amgen Announces 2019 Second Quarter Dividend

Amgen Announces 2019 Second Quarter Dividend

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.

Amgen To Present At The Cowen And Company 39th Annual Healthcare Conference

Amgen To Present At The Cowen And Company 39th Annual Healthcare Conference

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39 th Annual Healthcare Conference at 9:20 a.

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol

Video: Jim's Daily Rundown for Wednesday

Jim discusses the FDA approval of J&J's esketamine drug, the importance Disney's direct-to-consumer initiative, why you can't take your cue from a stock, and provides a view of Amgen.

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Jim Cramer analyzes what's driving the sellers and looks into this out-of-high-growth-into-value rotation.

Weekly Roundup

Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019

First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors

The New #34 Most Shorted Nasdaq 100 Component: Amgen

The New #34 Most Shorted Nasdaq 100 Component: Amgen

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Home Depot's earnings and the housing market, Macy's and Kohl's, the oil market, and much more!

Jury Upholds Amgen's Patents On Repatha® (evolocumab)

Jury Upholds Amgen's Patents On Repatha® (evolocumab)

THOUSAND OAKS, Calif., Feb.

Weekly Roundup

We made several trades this week as markets edged higher on optimism over a U.S.-China trade deal.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Behind the Cutting Edge Technology: The History of Amgen

Behind the Cutting Edge Technology: The History of Amgen

This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.

Weekly Roundup

Markets continued to move higher this week.

Last Week's Portfolio Changes

We lowered a price target and upgraded another position's rating last week.

TheStreet Quant Rating: B (Buy)